Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Is Agilent Stock A Good Buy Before Earnings?

Published 05/22/2017, 05:52 AM

Agilent Technologies Inc (NYSE:A) is an $18.12 billion company today. Investors that bought shares one year ago are sitting on a 25.94% total return. That's above the S&P 500's return of 16.29%.

Agilent stock is beating the market, and it reports quarterly earnings tomorrow. But does that make it a good buy today? To answer this question, we've turned to the Investment U Stock Grader. Our Research Team built this system to diagnose the financial health of a company.

Our system looks at six key metrics...

"EPS is an indicator of a company’s profitability and is considered to be one of the most important variables in determining a company’s share price. At Investment U and The Oxford Club, we look for companies that grow their earnings year-over-year." data-original-title="Earnings-per-Share">Earnings-per-Share (EPS) Growth:Agilent reported a recent EPS growth rate of 40.54%. That's below the healthcare sector average of 62.43%. That's not a good sign. We like to see companies that have higher earnings growth. " P/E is a valuation ratio of a company’s EPS compared to its current share price. Generally speaking, a high P/E means the market is bullish on a stock, but it can also signal that a stock is overpriced. What we look for is a stock trading below its industry average. This means we can get a better deal on a stock compared to its peers." data-original-title="Price-to-Earnings">Price-to-Earnings (P/E):The average price-to-earnings ratio of the healthcare sector is 32. And Foot Locker (NYSE:FL)'s ratio comes in at 32.20. The company looks expensive compared to many of its competitors.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Debt-to-Equity : The debt-to-equity ratio for Agilent stock is 46.33%. That's below the healthcare sector average of 59.09%. The company is less leveraged.

Free Cash Flow per Share Growth : Agilent's FCF has been lower than that of its competitors over the last year. That's not good for investors. In general, if a company is growing its FCF, it will be able to pay down debt, buy back stock, pay out more in dividends and/or invest money back into the business to help boost growth. It's one of our most important fundamental factors.

Profit Margins : The profit margin of Agilent comes in at 15.75% today. And generally, the higher, the better. We also like to see this margin above that of its competitors. Agilent's profit margin is above the healthcare average of 11.86%. So that's a positive indicator for investors.

Return on Equity (ROE) gives us a look at the amount of net income returned to shareholders. It tells us how much profit a company produces with the money shareholders invest. This is another metric that is useful in comparison to other companies in the same industry.

: Return on equity tells us how much profit a company produces with the money shareholders invest. The ROE for Agilent is 12.16%, and that's below its sector average ROE of 17.98%.

Agilent stock passes two of our six key metrics today. That's why our Investment U Stock Grader rates it as a Hold With Caution.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.